Drawing for POMALYST REMS

USPTO serial 85894252

POMALYST REMS

Reviewed by CopyMark Law Group

Reg. 4396293Status 800Registered
Filing date
Status date
Registration date
Sep 3, 2013
Examiner
HELFMAN, JUDITH MICHELLE
Law office
GENERIC WEB UPDATE

What this means

Status 800 means the registration was renewed after acceptable combined Section 8 and Section 9 filings. The mark remains registered for another 10-year term with active federal protection. Calendar the next Section 8 and 9 deadline in 10 years and maintain monitoring.

Status 800: Status 800 means the registration was renewed after acceptable combined Section 8 and Section 9 filings. The mark remains registered for another 10-year term with active federal protection.

Need help with POMALYST REMS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Marilyn F. Kelly

Marilyn F. Kelly Bristol-Myers Squibb CompanyPO BOX 4000Trademark Dept., Mailstop D.4243PRINCETON, NJ 08648

Goods and services

ClassDescriptionStatusFirst use
044Disease management and treatment programs that provide counseling and information in the field of pharmaceuticals, and distributing written materials in connection therewith; disease management and treatment programs that provide counseling and information regarding the pharmaceutical drug pomalidomide, and distributing written materials in connection therewithACTIVEFeb 8, 2013
045Government pharmaceutical programs that provide counseling and information to medical professionals, pharmacists and patients, including counseling and information on consumer product safety issues pertaining to pharmaceuticals, and distributing printed materials in connection therewith; government pharmaceutical programs that provide medical counseling and medical information regarding the pharmaceutical drug pomalidomide and safety issues pertaining to consumers' use of the pharmaceutical drug pomalidomide, and distributing written materials in connection therewithACTIVEFeb 8, 2013

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Feb 24, 2024NA89NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED—
Feb 24, 2024RNL1REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)The trademark registration was renewed for another 10-year term after acceptable maintenance filings. RNL1, RNL2, and RNL3 indicate which renewal cycle (first, second, or third 10-year term) was recorded. The registration remains active.
Feb 24, 202489AGREGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTEDThe USPTO accepted your combined Section 8 declaration and Section 9 renewal application. The registration is renewed for another 10-year term. The next combined maintenance filing will be due at the following 10-year anniversary.
Feb 23, 2024APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Aug 29, 2023E89RTEAS SECTION 8 & 9 RECEIVED—
Dec 9, 2022CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Dec 9, 2022TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Dec 9, 2022EWAFTEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS—
Dec 9, 2022ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Dec 9, 2022REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Dec 9, 2022COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Sep 3, 2022REM2COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED—
Sep 14, 2018NA85NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED—
Sep 14, 2018C15AREGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.—
Sep 14, 2018APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Sep 4, 2018E815TEAS SECTION 8 & 15 RECEIVED—
Sep 3, 2018REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Jul 29, 2015TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Sep 3, 2013R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jun 18, 2013NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jun 18, 2013PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
May 29, 2013NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
May 10, 2013PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
May 10, 2013ALIEASSIGNED TO LIE—
May 1, 2013CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Apr 30, 2013TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Apr 29, 2013CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Apr 29, 2013TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Apr 24, 2013GEANNOTIFICATION OF EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED—
Apr 24, 2013GEAPEXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED—
Apr 24, 2013EPENCOMBINED EXAMINER'S AMENDMENT/PRIORITY ACTION AUTOMATIC ENTRY—
Apr 24, 2013CPEAEXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED—
Apr 17, 2013DOCKASSIGNED TO EXAMINER—
Apr 9, 2013NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Apr 6, 2013NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance